Cytomegalovirus (CMV/HHV-5) Research Reagents — Antibodies & Recombinant Proteins

Glycoprotein B (gB/UL55)
gB is a class III fusion protein essential for viral entry into all cell types and the most advanced CMV vaccine target (GSK's gB/MF59 vaccine showed ~50% efficacy in transplant recipients). gB is also the dominant target for neutralizing antibodies in natural HCMV immunity. Available:
• Biosimilar-grade reference antibodies: Regavirumab (VK665016) and Fiztasovimab (VK665026)
• InVivoMAb neutralizing antibodies: clones SM5-1 (VK665010), Ab3-25 (VK665020), 1G2 (VK665030), and 8F9 (VK665040)
• Recombinant antibodies: clones SAA0288 (VK665013), VK665023, VK665033, and KSM15 (VK665043)
• Recombinant protein: gB ectodomain C-His (VK665011)

Pentameric Complex (gH/gL/UL128/UL130/UL131A)
The pentameric complex is required for HCMV entry into epithelial, endothelial, and myeloid cells — the cell types responsible for transplacental transmission and viral dissemination. Anti-pentamer antibodies are among the most potent CMV-neutralizing antibodies and are critical to next-generation CMV vaccine design. Available:
• InVivoMAb anti-UL128/UL131A (Iv0187, VK467010)
• Anti-UL130 recombinant antibody (8I21, VK480013)
• Recombinant proteins: UL128 N-His (VK467012), UL130 N-His (VK480012), UL130 C-Fc (VK480011)
• Polyclonal antibodies: anti-UL128 pAb (VK467014) and anti-UL130 pAb (VK480014)

Glycoprotein H (gH/UL75)
gH forms heterodimers with gL and is essential for membrane fusion. The gH/gL dimer also serves as a scaffold for pentamer assembly. Available:
• Sevirumab biosimilar reference antibody (VK705016)
• InVivoMAb anti-gH (Iv0180, VK705010)
• Anti-gH recombinant antibody (2-4#, VK705013)
• Recombinant proteins: gH C-His (VK705011), gH N-His (VK665012)
• Anti-gH polyclonal antibody (VK665014)

US28 (HHRF3) — Viral Chemokine Receptor
US28 is a constitutively active viral G-protein-coupled receptor (vGPCR) that hijacks host chemokine signaling to promote latency, immune evasion, and vascular disease. US28 is an emerging drug target and a potential biomarker for CMV reactivation. Available:
• InVivoMAb anti-US28 (Iv0102, VK595010)
• Anti-US28 nanobodies: SAA1150 (VK595013), SAA0899 (VK595023), SAA1107 (VK595033), and Nb7 (VK595043)

Tegument & Immediate-Early Proteins
• pp65/UL83 (major tegument phosphoprotein, T-cell immunodominant antigen): recombinant protein N-GST (VK643012) and polyclonal antibody (VK643014)
• IE1/UL123 (immediate-early transactivator): recombinant protein N-GST&C-His (VK663012)
• Assemblin/UL80 (capsid maturation protease): recombinant antibody SAA3009 (VK643013)

Which antibody targets are most important for CMV neutralization?
Complete HCMV neutralization requires targeting both fibroblast entry (via gB and gH/gL trimer) and epithelial/endothelial entry (via the gH/gL/UL128/UL130/UL131A pentameric complex). Anti-gB antibodies like SM5-1 neutralize fibroblast infection, while anti-pentamer antibodies like Iv0187 are needed for epithelial cell neutralization. Combining both provides broad protection.

What are the biosimilar-grade reference antibodies used for?
Regavirumab (VK665016), Fiztasovimab (VK665026), and Sevirumab (VK705016) are research-grade antibodies with sequences identical to clinical-stage anti-CMV therapeutic antibodies. They serve as positive controls, PK/ADA assay standards, and bioactivity reference materials in CMV therapeutic development programs.

Do you have reagents for CMV vaccine research?
Yes. Our portfolio covers all major CMV vaccine antigen candidates: gB ectodomain (VK665011), pentamer subunits (UL128/UL130), gH, and pp65. These can be used as coating antigens for ELISA-based immunogenicity assessment, competition assays, and as reference standards for vaccine-induced antibody characterization.

Explore reagents for related herpesviruses:

HSV-1 (HHV-1) HSV-2 (HHV-2) VZV (HHV-3) EBV (HHV-4) CMV (HHV-5) ✓ Pseudorabies (PRV)